Coronary Artery Disease Clinical Trial
— TRANSFORM IOfficial title:
Magic Touch Sirolimus Coated Balloon (Concept Medical) Versus SeQuent Pease Neo Paclitaxel Coated Balloon (Bbraun) for the Treatment of de Novo Coronary Artery Lesions in Small Vessels
Verified date | October 2022 |
Source | Concept Medicals BV |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a prospective, multinational (Italy, Ireland and UK), multicenter, randomised Clinical Trial that compares the efficacy and performance of two drug coated balloon (DCB), the MAGIC TOUCH sirolimus coated balloon (Concept Medical) and SeQuent Please paclitaxel coated balloon (B Braun). The objective of the study is to compare angiographic outcomes of Magic TouchTM sirolimus coated balloon (Concept Medical) versus SeQuentTM paclitaxel coated balloon (Bbraun) for the treatment of de novo coronary artery lesions in small vessels (≤2.75 mm) with respect to Net Gain (mm) at 6 months follow-up
Status | Active, not recruiting |
Enrollment | 121 |
Est. completion date | September 10, 2023 |
Est. primary completion date | March 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female patients =18 years 2. Patient with chronic stable angina or stabilized acute coronary syndromes with normal cardiac biomarker values Note: For patients showing elevated Troponin (e.g. non-STEMI patients) at baseline (within 72h pre-PCI) an additional blood sample must be collected prior to randomization to confirm that: - hs-cTn or Troponin I or T levels are stable, i.e. the value should be within 20% range of the value found in the first sample at baseline, or have dropped - CK-MB and CK levels are within normal range If hs-cTn or Troponin I or T levels are stable or have dropped, the CK-MB and CK levels are within normal ranges, and the ECG is normal, the patient may be included in the study. 3. The patient has a planned intervention in one or two separate major epicardial territories (LAD, LCX or RCA) and has at least one de-novo lesion in a small vessel (=2.75mm by QCA prior to pre-dilatation) 4. Target lesion length =30 mm 5. Able to understand and provide informed consent and comply with all study procedures including 6 months angiographic follow-up 6. Patient must have completed the follow-up phase of any previous study Exclusion Criteria: 1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential) 2. Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of procedure 3. Known contraindication or hypersensitivity to sirolimus, paclitaxel, or to medications such as aspirin, heparin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor 4. Patient suffered from stroke/TIA during the last 6 months 5. LVEF <30% 6. Platelet count <100,000 cells/mm3 or >400,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis) 7. Known renal insufficiency (e.g. serum creatinine >2.5mg/dL, or creatinine clearance =30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment) 8. Patient undergoing planned surgery within 6 months with the necessity to stop DAPT 9. History of bleeding diathesis or coagulopathy 10. The patient is a recipient of a heart transplant 11. Concurrent medical condition with a life expectancy of less than 12 months 12. The patient is unwilling/not able to return for angiographic recatherisation at 6 month follow-up 13. Currently participating in another trial and not yet at its primary endpoint. Angiographic exclusion criteria: 14. The patient has a planned intervention in three separate major epicardial territories (3 vessel disease) 15. The patient has a planned intervention in the left-main plus two separate major epicardial territories (left-main plus 2 vessel disease) 16. Target vessel size >2.75 mm (by QCA) 17. Target vessel size <2.00 mm (by QCA) 18. Target lesion has a total occlusion or TIMI flow <2 19. Target lesion in left main stem 20. The target vessel contains visible thrombus 21. Aorto-ostial target lesion (within 3 mm of the aorta junction) 22. Moderate-severe tortuous, calcified or angulated coronary anatomy of the target vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter 23. Lesion is located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft. |
Country | Name | City | State |
---|---|---|---|
Ireland | Galway University Hospital | Galway | |
Italy | Maria Cecilia Hospital spa | Cotignola | Emilia-Romagna |
Italy | AOUC Azienda Ospedaliero-Universitaria Careggi | Firenze | Tuscany |
Italy | Istituto Clinico Humanitas | Rozzano | |
Italy | I.R.C.C.S. Policlinico San Donato | San Donato Milanese | Lombardy |
United Kingdom | Heart of England NHS Trust, Heartlands Hospital | Birmingham |
Lead Sponsor | Collaborator |
---|---|
Concept Medicals BV |
Ireland, Italy, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Net Gain (mm) In-segment | The primary endpoint is in-segment (balloon treated area) Net Gain (mm) at 6 months post-procedure. | 6 Months | |
Secondary | Device success | Successful delivery and inflation within 45 seconds of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use) and successful withdrawal of the device system with attainment of final in-lesion residual stenosis of <30% (by Quantitative Coronary angiography). | Post procedure (Right after the treatment with drug coated balloon) | |
Secondary | Procedure Success | Successful delivery and inflation within 45 seconds of the allocated DCB device at all intended target lesion(s) during an attempt with a DCB not previously used (first use) and successful withdrawal of the device system with attainment of final in-lesion residual stenosis of <30% (by QCA) without the occurrence of TLF during the index procedure hospital stay). | Post procedure (Right after the treatment with drug coated balloon) | |
Secondary | Acute/subacute/early/late vessel closure/thrombosis | Closure by restenosis or thrombosis (diameter stenosis of 100% and/or TIMI grade 0). | 1, 6 months and 12 Months | |
Secondary | Angiographic outcomes: late lumen loss | The difference between the minimum lumen diameter (MLD) immediately after index procedure and the MLD at follow-up as measured in (preferable) identical orthogonal views (MLDpost - MLDfup). | 6 months | |
Secondary | Angiographic outcomes:Minimal lumen diameter | The smallest lumen diameter in the segment of interest | 6 months | |
Secondary | Angiographic outcomes: Percent diameter stenosis | The percentage of luminal narrowing of vessel segment of interest | 6 months | |
Secondary | Angiographic outcomes: Restenosis rate | Restenosis is defined as =50% diameter stenosis at follow-up. | 6 months | |
Secondary | Device oriented Composite Endpoint (DoCE / TLF): Cardiac death | Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment. | 1, 6 months and 12 Months | |
Secondary | Device oriented Composite Endpoint (DoCE / TLF): Target vessel: myocardial infarction (TV-MI) | The term myocardial injury should be used when there is evidence of elevated cardiac troponin values (cTn) with at least one value above the 99th percentile upper reference limit (URL) TV-MI: Myocardial Infarction not clearly attributable to a non-target vessel. | 1, 6 months and 12 Months | |
Secondary | Device oriented Composite Endpoint (DoCE / TLF): clinically indicated target lesion revascularization(TLR) | TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. | 1, 6 months and 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |